Aug 21 (Reuters) - Opthea Ltd OPT.AX :
* OPTHEA COMPLETES SUCCESSFUL MEETINGS WITH FDA AND EMA FOR OPT-302 PHASE 3 CLINICAL PROGRAM IN WET AMD
* OUTCOME OF MEETINGS SUPPORTS PROGRESSION OF OPT-302 INTO PHASE 3 AND PRE-COMMERCIAL DEVELOPMENT
* ON-TRACK TO INITIATE PHASE 3 TRIALS IN EARLY 2021